Search results
Results from the WOW.Com Content Network
The Common Terminology Criteria for Adverse Events (CTCAE), [1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).
CRS is a form of systemic inflammatory response syndrome and is an adverse effect of some drugs. [5] The Common Terminology Criteria for Adverse Events classifications for CRS as of version 4.03 issued in 2010 were: [5] [20]
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (as described in the American Academy of Audiology Ototoxicity Monitoring Guidelines from 2009): [8] Grade 1: Threshold shift or loss of 15-25 dB relative to baseline, averaged at two or more contiguous frequencies in at least one ear
A risk management plan is a documented plan that describes the risks (adverse drug reactions and potential adverse reactions) associated with the use of a drug and how they are being handled (warning on drug label or on packet inserts of possible side effects which if observed should cause the patient to inform/see his physician and/or ...
Adverse events categorized as "serious" (results in death, illness requiring hospitalization, events deemed life-threatening, results in persistent or significant incapacity, a congenital anomaly or medically important condition) must be reported to the regulatory authorities immediately, whereas non-serious adverse events are merely documented ...
There are currently several grading scales that exist to assess vaginal stenosis but none have been well established. Two common grading scales are the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v4.0 and the Late Effects in Normal Tissues-Subjective, Objective, Management and Analytic Score (LENT-SOMA). [1]
Acral erythema is a common adverse reaction to cytotoxic chemotherapy drugs, particularly cabozantinib, cytarabine, doxorubicin, and fluorouracil and its prodrug capecitabine. [3] Targeted cancer therapies, especially the tyrosine kinase inhibitors sorafenib and sunitinib, have also been associated with a high incidence of acral erythema ...
1 CTCAE version 4 - update needed to this page. Toggle the table of contents. Talk: Common Terminology Criteria for Adverse Events. Add languages.